Interview with Sergio Duplan, CPO Head & Country President Mexico, Novartis…
Carlos Garcia said in December 2009 that 6-8% of Novartis’ annual revenue comes from Latin America, and that the area is “one of the main growth engines for the company”.…
Address: Calzada de Tlalpan #1779, Colonia San Diego Churubusco, Mexico D.F.,Mexico
Tel: (55) 5420-8600
Web: http://www.novartis.com.mx/10ybrand/NOVARTIS_WEB_2009/Soft_Templates/index.html
In Mexico, the Novartis Group consists of Novartis Pharmaceuticals, Sandoz, OTC, CIBA Vision, Novartis Animal Health, and Novartis Vaccines and Diagnostics. More than 1,700 employees and more than $7 billion MXP sales revenue in 2011.
Novartis Pharmaceuticals (patented medicines), Sandoz (generic products), OTC (prescription free medicines), CIBA Vision (provider of high technology contact lenses and their care products), Novartis Animal Health (health care for pets and livestock) and Novartis Vaccines and Diagnostics (vaccines and clinical diagnostic products).
Carlos Garcia said in December 2009 that 6-8% of Novartis’ annual revenue comes from Latin America, and that the area is “one of the main growth engines for the company”.…
Dr. Marco A. Martinez Rios, General Director of the National Institute of Cardiology in Mexico elaborates on the institution’s rich history in Mexico and its contributions to cardiology through research,…
Andrés Matesanz, general manager at DCS Pharma Mexico, explains how the merger between Dolder and Chemswiss has enlarged the capabilities and the offering of the company in Mexico and showcases…
José Alberto Peña, managing director at Marzam Mexico, showcases the benefits that distributors can offer to the healthcare and life science sector as well as Marzam’s strategy to overcome the…
Carlos Pérez Muguía, CEO at NYCE, showcases the increasing added value brought by this leading Cofepris’ authorized third party (ATP) to the healthcare industry, the future objectives of the company…
Alan Smithers, CEO at IFA Celtics, highlights the obesity as a national healthcare challenge and explains the company’s strategy to enlarge its capabilities to cope with the increasing needs of…
Salomon Rayek, CEO at Sinbiotik, explains how the company managed to adapt its business model to the industry trends and showcases the added value of Sinbiotik when offering high quality,…
Due to economic necessity, the Mexican government is attempting to slash annual spending; an act that could have serious consequences on the country’s ability to provide its citizens with healthcare.…
Francisco Rodriguez, general manager Mexico and Latin America at Mundipharma, provides an overview of the customized market approach that has allowed the company to establish itself as the partner of…
Jorge Romero Castañeda and María Eugenia Mendez, Healthcare & Life Science leader and Strategy & Operations Director at Deloitte respectively, share their expertise about the Healthcare & Life Science sector…
Leonardo Torres, general manager Mexico, Central America & Caribbean of Shire, provides insights into the rapidly progressing integration of Baxalta in Mexico, while he also highlights his key priorities to…
Mario Sturion, the recently appointed general manager of Janssen Mexico, assesses the specific challenges and opportunities of the Mexican health system and explains how a customized market access approach has…
Jaime Cervantes, CEO of Vitalmex, provides insights into the company’s ascendent trajectory, with Vitalmex now looking to leverage its leadership position in the public sector to venture in the private market,…
See our Cookie Privacy Policy Here